Pay in 4 interest-free payments of $6.66 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
*******If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact us.
Results vary based on dosage, consistency, and individual metabolism
Disclaimers *Currently available in the following states: AZ, CA, CO, CT, FL, GA, IL, IN, KS, KY, MA, MD, MI, MN, MO, NC, NJ, NV, NY, OH, OK, PA, SC, TN, TX, VA, WA, WI
Tirzepatide 2.5 mg activates both GLP-1 and GIP receptors, while semaglutide 0.25 mg activates only GLP-1 receptors
Since semaglutide 2.4 mg once-weekly, which is a FDA/EMA-approved weight loss drug in the USA and Europe, was not yet approved for the treatment of obesity at the time the study was conducted, patients of our cohort received a maximum dose of 0.5 mg once-weekly
US$ 21.87
US$ 22.56
US$ 25.04
US$ 22.51
US$ 20.40
